Home › Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes
 

Keywords :   


Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes

2013-03-28 09:57:29| dairynetwork News Articles

Biodel Inc. (Nasdaq:BIOD) today announced the completion of patient enrollment in a Phase 2 clinical study of ultra-rapid-acting prandial insulin candidate BIOD-123 for the treatment of diabetes. The trial will evaluate the use of BIOD-123 versus Humalog® on measures of HbA1c, postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes.

Tags: the of treatment trial

Category:Agriculture and Forestry

Latest from this category

All news
27.11Washington Corner | November 2024
27.11Pork Checkoff continues building a bigger appetite for pork
27.11Terminal crossbreeding: A missed opportunity
27.11Feedlot Forum 2025 features Cattle feeding in a changing environment
27.11Smithfield Foods continues support for Mayflower Marathon Holiday Food Drive
27.11Researchers turn to AI to optimize hog selling
27.11H5N1 in pigs: Where are the knowledge gaps?
26.11New swine respiratory disease treatment flexibility from nursery to finish
Agriculture and Forestry »
28.11 HEXAGON TR SET UP
28.1121dc hg
28.111EX D
28.11 Bucchus IMP24 FMH-RSM/M
28.11
28.11specialites TA carmina 46-36
28.11HUNTER×HUNTER
28.11
More »